U.S. COMPANY FILING
VERTEX PHARMACEUTICALS INC / MA — Form 10-Q filed 2026-05-05
Filing text preview
Vertex Pharmaceuticals reported Q1 2026 total revenues of $2.99 billion, up 8.2% year-over-year, driven by growth in TRIKAFTA, ALYFTREK, CASGEVY, and JOURNAVX. Net income rose 59.6% to $1.03 billion. R&D expenses decreased slightly, while SG&A increased. The company repurchased $344.5 million of stock and disclosed an arbitration with Royalty Pharma regarding ALYFTREK royalty burden.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record